# DBPR108 Tablets in Type 2 Diabetes Mellitus Patients

> **NCT04124484** · PHASE2 · COMPLETED · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 276 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** DBPR108 tablet(50mg), Placebo matching DBPR108 tablet(100mg)
- **DRUG:** DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg), Placebo matching DBPR108 tablet(100mg)
- **DRUG:** DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg)
- **DRUG:** Placebo matching DBPR108 tablet(100mg), Placebo matching DBPR108 tablet(50mg)

## Key facts

- **NCT ID:** NCT04124484
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-17
- **Primary completion:** 2019-02-27
- **Final completion:** 2019-06-28
- **Target enrollment:** 276 (ACTUAL)
- **Last updated:** 2019-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04124484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04124484, "DBPR108 Tablets in Type 2 Diabetes Mellitus Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04124484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*